Total Payments
$156,974
2024 Payments
$9,854
Companies
15
Transactions
140
Medicare Patients
4,326
Medicare Billing
$269,242
Payment Breakdown by Category
Other$100,107 (63.8%)
Consulting$37,760 (24.1%)
Travel$13,175 (8.4%)
Food & Beverage$4,079 (2.6%)
Research$1,851 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $100,107 | 41 | 63.8% |
| Consulting Fee | $37,760 | 11 | 24.1% |
| Travel and Lodging | $13,175 | 19 | 8.4% |
| Food and Beverage | $4,079 | 67 | 2.6% |
| Unspecified | $1,851 | 2 | 1.2% |
Payments by Type
General
$155,122
138 transactions
Research
$1,851
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $145,329 | 110 | $0 (2024) |
| Genentech USA, Inc. | $4,732 | 6 | $0 (2020) |
| Boehringer Ingelheim International GmbH | $2,083 | 5 | $0 (2021) |
| United Therapeutics Corporation | $1,924 | 5 | $0 (2023) |
| F. Hoffmann-La Roche AG | $1,710 | 1 | $0 (2022) |
| Eli Lilly and Company | $500.00 | 1 | $0 (2019) |
| ANI Pharmaceuticals, Inc. | $232.39 | 2 | $0 (2023) |
| Biogen, Inc. | $140.92 | 1 | $0 (2019) |
| Mallinckrodt LLC | $120.86 | 1 | $0 (2018) |
| Genentech, Inc. | $96.76 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,854 | 8 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,854) |
| 2023 | $17,096 | 18 | Boehringer Ingelheim Pharmaceuticals, Inc. ($16,622) |
| 2022 | $14,456 | 13 | Boehringer Ingelheim Pharmaceuticals, Inc. ($12,733) |
| 2021 | $9,609 | 8 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,547) |
| 2020 | $27,000 | 19 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21,915) |
| 2019 | $48,071 | 37 | Boehringer Ingelheim Pharmaceuticals, Inc. ($47,298) |
| 2018 | $30,391 | 32 | Boehringer Ingelheim Pharmaceuticals, Inc. ($30,241) |
| 2017 | $496.33 | 5 | Genentech USA, Inc. ($359.86) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 12/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $36.61 | General |
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| 11/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: RESPIRATORY | ||||||
| 11/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| 09/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $121.64 | General |
| 05/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $78.62 | General |
| 01/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| 11/13/2023 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 11/09/2023 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $123.11 | General |
| 11/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| 11/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 09/21/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $1,637.30 | General |
| 09/21/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $120.15 | General |
| 06/20/2023 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $209.04 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 06/20/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $14.35 | General |
| 06/20/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $14.35 | General |
| 06/20/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $1.68 | General |
| 06/19/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $1.68 | General |
| 05/23/2023 | Genentech, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $96.76 | General |
| Category: Immunology | ||||||
| 05/22/2023 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $21.70 | General |
| 04/06/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: RESPIRATORY | ||||||
| 01/11/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| 01/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $8,240.00 | General |
| Category: RESPIRATORY | ||||||
| 01/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $140.00 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LONG-TERM EVALUATION OF THE SAFETY AND EFFICACY OF RECOMBINANT HUMAN PENTRAXIN-2 RHPTX-2 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS IPF AN OPEN-LABEL EXTENSION STUDY | F. Hoffmann-La Roche AG | $1,710 | 1 |
| An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis | Biogen, Inc. | $140.92 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,261 | 1,420 | $287,664 | $62,772 |
| 2022 | 15 | 1,101 | 1,215 | $233,258 | $57,470 |
| 2021 | 15 | 1,057 | 1,249 | $263,790 | $71,856 |
| 2020 | 13 | 907 | 1,117 | $262,145 | $77,144 |
Total Patients
4,326
Total Services
5,001
Medicare Billing
$269,242
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 101 | 114 | $24,555 | $11,851 | 48.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 53 | 116 | $30,206 | $10,542 | 34.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 25 | 52 | $38,700 | $8,442 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 69 | 79 | $17,304 | $8,092 | 46.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 40 | 40 | $13,060 | $4,924 | 37.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 29 | 29 | $12,907 | $3,842 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 43 | $8,370 | $2,648 | 31.6% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 198 | 201 | $46,852 | $1,808 | 3.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 28 | 28 | $5,178 | $1,709 | 33.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $4,468 | $1,531 | 34.3% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 223 | 227 | $20,561 | $1,517 | 7.4% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 223 | 233 | $29,213 | $1,413 | 4.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 30 | 53 | $3,976 | $1,261 | 31.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 15 | $2,640 | $906.00 | 34.3% |
| 94621 | Test for exercise-induced heart and lung stress | Facility | 2023 | 13 | 13 | $4,083 | $673.01 | 16.5% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 73 | 73 | $16,963 | $569.62 | 3.4% |
| 94618 | Test for exercise-induced lung stress | Facility | 2023 | 38 | 38 | $4,554 | $564.29 | 12.4% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Facility | 2023 | 52 | 53 | $4,074 | $479.71 | 11.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 90 | 99 | $17,326 | $10,091 | 58.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 26 | 52 | $32,250 | $8,590 | 26.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 69 | 79 | $14,110 | $7,224 | 51.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 40 | 41 | $19,475 | $6,152 | 31.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 35 | 35 | $10,674 | $3,973 | 37.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 51 | $12,495 | $3,962 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 49 | 49 | $8,169 | $3,556 | 43.5% |
About Dr. Mark Hamblin, MD
Dr. Mark Hamblin, MD is a Internal Medicine healthcare provider based in Kansas City, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1588758502.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Hamblin, MD has received a total of $156,974 in payments from pharmaceutical and medical device companies, with $9,854 received in 2024. These payments were reported across 140 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($100,107).
As a Medicare-enrolled provider, Hamblin has provided services to 4,326 Medicare beneficiaries, totaling 5,001 services with total Medicare billing of $269,242. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Kansas City, KS
- Active Since 10/03/2006
- Last Updated 06/20/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1588758502
Products in Payments
- OFEV (Drug) $95,345
- Esbriet (Biological) $4,499
- PURIFIED CORTROPHIN GEL (Drug) $232.39
- TYVASO (Drug) $139.06
- ACTHAR (Biological) $120.86
- Xolair (Biological) $96.76
- Arikayce (Drug) $31.82
- ZERBAXA (Drug) $16.22
- GLASSIA (Biological) $14.39
- TRELEGY ELLIPTA (Drug) $12.33
- BREZTRI (Drug) $12.01
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Kansas City
James O'keefe, Md, MD
Internal Medicine — Payments: $834,178
Internal Medicine $834,178
Shadi Hamdeh, Md, MD
Internal Medicine — Payments: $623,244
Internal Medicine $623,244
Dr. Patrick Moriarty, M.d, M.D
Internal Medicine — Payments: $618,967
Internal Medicine $618,967
Gerald Mancuso, M.d, M.D
Internal Medicine — Payments: $615,894
Internal Medicine $615,894
Dr. Ryan Taylor, M.d, M.D
Internal Medicine — Payments: $512,094
Internal Medicine $512,094
Sanjaya Gupta, Md, MD
Internal Medicine — Payments: $325,155
Internal Medicine $325,155